The Pharma Intelligence Awards will be judged by a panel of industry experts within academia and business, from around the globe. Each of the judges brings a wealth of specialist knowledge, experience and expertise, carefully selected for their credibility and objectivity.
The Judging process takes place between February and March 2022. The Judging Panel is independent and considers entries objectively; each category entry is reviewed by at least three, individual judges. The judges score each entry against the listed criteria for the category, and the scores are marked out of ten for each category answer. The Awards team collate the scores to determine which entries are included in the shortlist, and the ultimate winner.
The chair of the Judging Panel reserves the right to cast any deciding vote, should the need arise. The judges’ decision is final - neither the organizers, nor the Judging Panel, will enter into any correspondence about the results. Details of the winners are strictly embargoed until the Awards night, but details of all the shortlisted entries will be listed once available.
Please see the judges below
Dr Shoichiro Hamano
Dr Yujiro Maeda
Dr Noboru Yamamoto
CEO, Renexes LLC, ex-President, Mundipharma Japan and Solasia Pharma
Steve brings over 20 years of senior executive level operating and transaction experience in the biopharmaceutical industry, with expertise in Japanese/Asian markets. In 2014, he established his own biopharma consultancy, and continues to support Japanese, Chinese, and western biopharma clients. From 2014 until May 2018, Steve was Managing Director and Head of Asia for Locust Walk, where he established the Locust Walk Japan office. During the four years that Steve ran the Locust Walk Japan office, he oversaw eleven transactions (including buy-side and sell-side transactions) between western and Asian companies.
Steve previously headed the Japanese operations of Shire Pharmaceuticals. Before Shire, Steve served as CEO of Solasia Pharma, a cancer-focused development stage company. Raising over $40MM in venture capital, he built a portfolio of novel cancer drugs and established operations in Japan and China. Steve launched his biopharma career at Purdue Pharma in business development, and then held the position of President of Mundipharma Japan for nine years. In this role, he oversaw the development and commercialization of the company’s leading pain management franchise.
Steve, his wife, and two daughters currently have their primary residence in Bellevue, Washington. Steve is fluent in written and spoken Japanese.
Dr Shoichiro Hamano
CEO, Hamano International
He is a recipient of the U.S. FDA Commissioner's Special Award and a former ICHGMP EWG member and received his PhD from the University of Tokyo and his Master's degree from Kanazawa University, in pharmacy, a registered Pharmacist, involved in new business development, technology transfer, licensing, negotiation, contract drafting, JV establishment, and M&A for 25 years in big pharma.
His areas of expertise include licensing, technology transfer, new business development, start-up consulting and related services, currently serves as an adviser to the Toyama Pharmaceutical Association. He also served as the Senior Vice President of KUTLO-NITT (TLO Union), as CD of Hokuriku Innovation Cluster for Health Science and adviser to the DBJ VC "BHP".
He has visited more than 250 venture companies in the world and made business contacts with more than 350 leading pharmaceutical companies in Japan and overseas. Traveled overseas more than 300 times.
Office is located in Nihonbashi, Tokyo, the center of Japan's pharmaceutical industry.
Managing Director, Zinagi Consulting
Thomas established Zinagi, a lifescience consulting company, in 2013 and has successfully supported innovative medical device, medical software, and biotech companies. Thomas previously served as Lifescience Ambassador for Medicon Valley Alliance and prior to that held commercial positions at several global big pharma companies.
Professor, University of Tokyo/Graduate School of Frontier Sciences
Shingo Kano is a Professor in Bio-Innovation Policy Unit, Graduate school of Frontier Science, the University of Tokyo, where he also completed his PhD in Science Policy. He had a varied career in industry as management consultant in Nomura Research Institute, securities analyst and venture capitalist for the healthcare sector in Nomura Securities and run the university spin off drug discovery firm as president and CEO for ten years before starting his academic career.
His current research focuses on the recognition gap between university and industry, the role and management of university spin off, how regulation and innovation interact in the advanced industries, and the changing role of universities and companies in the national innovation systems.
Professor, Graduate School of Medicine, Kyoto University
Graduated from the University of Tsukuba School of Medicine (doctor's license) in 1997, and graduated from Yokohama City University Graduate School of Medicine (Doctor of Medicine) in 2001. He has served as a clinical trial examiner and researcher in the Department of Cell Gene Therapy at the US Federal Food and Drug Administration (FDA) Biopharmaceutical Evaluation and Research Center (CBER), and is engaged in clinical trial review work and administrative guidance in the United States.
After working as a visiting assistant professor at the Graduate School of Medicine, the University of Tokyo, he became a professor at Kyoto University at the age of 33 in 2006 (Graduate School of Medicine, Department of Social Health Medicine, Drug Epidemiology). 2010-2014 Assistant Director of Kyoto University (Research), 2011 Director of Science Unit for Interdisciplinary Education and Research Promotion Center, Kyoto University.
He also serves as a visiting professor at Keio University School of Medicine. There are more than 160 original papers.
Dr Yujiro Maeda
Director, Department of Biodesign, The University of Tokyo Hospital
Co-founder, Premo Partner Inc.
Director, Aillis Inc.
Co-founder and Chairman, Kozue Medical Group
Global Faculty, Stanford Biodesign
Co-Director, Japan Biodesign
Specially Appointed Professor, Tokyo University of Pharmacy and Life Sciences
Visiting Lecturer, Waseda University Business School
Yujiro has promoted the development of medical technology that starts from the needs of the medical field.
He completed doctor course in Medicine from the University of Tokyo Graduate School of Medicine & School of Dentistry in Kyushu University. He engaged in clinical practice at the University of Tokyo Hospital, Department of Oral and Maxillofacial Surgery, Department of Orthodontics, and Emergency Department. In 2013, he was engaged in tele-health business in the Pharmaceutical Business Planning Department of Otsuka Pharmaceutical Co.
In June 2014, he completed the Global Faculty training program at Stanford University's Biodesign Program, a program to develop innovators for medical device invention and entrepreneurship. In 2015, he founded Japan Biodesign and started 0→1 acceleration of medical deep technology startups. Since then, he has been co-director of Japan Biodesign. In the same year,he was assigned to be a global member of SPARK, Stanford University's translational program for drug discovery and biotechnology. In 2020, he became the Director of the Department of Biodesign, Translational Research Center, University of Tokyo Hospital.
In 2018, he became a director of Aillis Inc., a medical AI startup, and in 2019, he co-founded Premo Partner Inc. and started advising major manufacturers on new business, incubating medical startups, and angel investing.
He is also a Specially Appointed professor at Tokyo University of Pharmacy and Life Sciences (2020-), a visiting lecturer at Waseda University Business School (2018-), Advisor to Eten Lab Inc. which provides "Minchare", a program to change society through behavioral change (2016-). Co-Founder of Vice-Director of Kozue Medical Corporation(2019-).
CEO, Miyata Institute of Technologies/Healthcare Innovation
Mr. Miyata joined Nikkei Inc. in 1979 after completing a postgraduate degree in Botany at the University of Tokyo. Mr. Miyata then worked in the editorial department of Nikkei medical and was involved in the launch of Nikkei biotech. Mr. Miyata was then appointed as the Editor-in-Chief of Nikkei biotech in 1985. In July 2015, Mr. Miyata founded the Miyata Institute of Technologies and became the President. Then in April 2017, he founded Healthcare Innovation and was appointed it’s President.
He is also involved in various public activities such as being the Ministry of Health, Labour and Welfare and AMED.
Senior Analyst/Director, Credit Suisse Securities
After graduating from Arizona State University with a degree in Finance, Mr. Sakai joined Imperial Chemical Industries Japan, a British chemical company, where he worked for five years in Japan and the UK. Mr. Sakai then joined the Corporate Research Department of the Economic Research Institute of Yamaichi Securities. After this, Mr. Sakai joined Société Générale, working within Domestic Equities and the Corporate Research Department in 1998. Since 2002, he has worked as an analyst for the pharmaceutical industry in Deutsche Securities' Equities Research Department. Mr. Sakai joined Credit Suisse First Boston Securities (now Credit Suisse Securities (Japan) Limited) in July 2005 where he worked as a Senior Analyst and Director in the Equity Research Department. In both 2008 and 2009, Mr. Sakai was ranked third in the pharmaceutical sector by Institutional Investor magazine. He is a member of the Securities Analysis Association of Japan. He is also the author of several books.
Dr Noboru Yamamoto
Deputy Director of National Cancer Center Hospital
Director / Clinical Research Support Office
Director / Department of Experimental Therapeutics
Head of Physician / Department of Thoracic Oncology
Dr. Yamamoto graduated from Hiroshima University School of Medicine in 1991 and started his residency in internal medicine at the National Cancer Center Hospital in 1995. Dr. Yamamoto became a physician in the Department of Respiratory Medicine at the National Cancer Center Hospital in 2000, and in 2013 he progressed to Director of the Department of Advanced Medicine there. Since 2019, Dr Yamamoto has worked as the Director of the Division of Clinical Research Support and Deputy Director of the National Cancer Center Hospital. Dr Yamamoto specializes in the early clinical development of novel anticancer agents, thoracic oncology and clinical pharmacology. Dr. Yamamoto received the ASCO Merit Award in 1996, 1999 and 2000, and has been a member of the editorial board of the Japanese Journal of Clinical Oncology since 2005.